Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AACR, abrupt, absorb, adjournment, adoptedEITF, AIG, Alastair, alive, andEITF, angina, appoint, appointed, appointment, ARB, ARVO, attestation, autoimmune, backbone, bailout, beneficiary, bid, Biennial, billion, biomarker, bond, brain, cardiovascular, cast, cease, classification, colon, constantly, constrast, consummation, cooperative, corroborate, cytoskeleton, cytoxic, degradation, departure, depolymerization, doubt, drawdown, earliest, Edelman, elevated, encumber, engineering, enjoy, enterprise, enzyme, Eric, exceed, exited, expert, facto, FALCON, fall, fatigue, ForceNo, fragile, hand, headache, Hedging, hepatic, hierarchy, hypertension, Iceland, illustrated, ImClone, immature, indeterminable, ineffective, Intermittently, invasive, invoiced, IRC, ischemia, JDC, journalSciencethat, journalThyroid, judgment, Kessel, kidney, Liechtenstein, lieu, liver, LLC, LP, lymph, mandate, mandatory, meaningfully, moderately, monthly, mutually, myeloid, myocardial, Myriad, nausea, NCE, nephrotic, neurodegenerative, Nicole, node, noncontrolling, nonfinancial, Novated, Obama, obviate, occlude, officially, ofnew, OMX, Onetto, ophthamology, orthoquinone, ovary, oversee, overseen, oxidative, Oxley, pain, panel, payer, pegaptanib, perforation, Policiesunder, poorly, proportionate, proteinuria, quorum, quoted, ranibizumab, rata, ratified, rationale, rectum, Reinvestment, remeasured, Remick, representation, residual, resignation, robust, Rowinsky, RRD, satisfaction, scenario, Scot, Seperately, skin, smaller, solicit, sorafenib, spending, standing, straightforward, sublet, subordinated, sunitinib, Symphony, syndrome, theexistingblood, thromboembolic, transaction, transient, treatement, unconfirmed, unfair, unobservable, unproven, unresponsive, USAN, variability, variable, vascularly, vi, vida, VIE, vii, viii, vomiting, Wood, worth, ZBYRESTAT, ZYBERESTAT, ZYBRETAT
Removed:
Abbott, acceptance, accurately, adjacent, Adjunct, Aeterna, affordable, African, AG, ago, aimed, Akerley, alternate, Army, assessed, Assistant, attacking, author, authored, bark, Bayer, Beth, biology, Biomolecular, Birmingham, blockade, broadened, Brook, bush, caffrum, cancelled, carcinoma, certainty, charity, Citron, Cleveland, cohort, coincided, compatibility, compound, compromising, conditioned, Conference, conform, conventional, core, curing, damage, decade, deducting, deduction, define, delivery, deprive, desire, detect, detection, discovered, Disposal, disposition, distinguishable, Division, dosed, dramatic, Dutch, editorial, efficient, elongated, emerge, Emission, enhance, EntreMed, EORTC, equivalent, ESMO, esophageal, evaluable, examined, experimental, expired, Fabre, family, fighting, focal, focused, focusing, forward, found, foundation, Genentech, germ, GlaxoSmithKline, Gray, grow, guarantee, Harvard, hematology, hire, Honorary, Huntsman, immunotherapy, incurable, induce, innovation, inoperable, insight, instructorship, instrumentation, intact, Integrated, integrity, internationally, internship, invest, investigate, investigated, Ireland, isolated, Israel, Johnson, journal, kill, landlord, larger, leading, leased, lectured, led, Magdalen, Magnetic, matching, metastasized, Middlesex, Millennium, mode, moved, narrow, naturally, NeoPharm, newer, Oak, offering, OM, OQP, ordinarily, ostensibly, owed, performing, peripheral, periphery, persist, pertain, Pfizer, Pharmacodynamic, Pharmacology, Pierre, placement, point, Positron, postgraduate, preclinical, prevalent, prodrug, Professorship, progressed, progressive, projected, promissory, prostate, pursued, Radiumhemmet, recently, recipient, reclassified, regrowth, relocated, renal, reoccupy, researching, reside, residency, resistance, Resonance, rim, Robinson, scientist, Secretary, served, settlement, shutting, signal, stated, stream, subtenant, suitable, summarized, surgical, surviving, targeting, Tempe, termed, Throughin, today, tomography, training, transitional, trend, triple, UCLA, unamortized, undiscounted, unqualified, Utah, vital, vitroandin, vivotesting, vote, Wallace, weekly, willow, worldwide, Zecher
Filing tables
Filing exhibits
- 10-K Annual report
- 10.51 EX-10.51 409A Amendment to Employment Agreement MR. Chaplin
- 10.52 EX-10.52 409A Amendment to Employment Agreement MR. Kollins
- 10.53 EX-10.53 409A Amendment to Employment Agreement MR. Murphy
- 10.54 EX-10.54 409A Amendment to Employment Agreement DR. Walicke
- 10.55 EX-10.55 Amendment No 2 to Employment Agreement DR. Chaplin
- 10.56 EX-10.56 Amendment No 2 to Employment Agreement MR. Murphy
- 10.57 EX-10.57 Research and Development Agreement Vida Holdings
- 10.58 EX-10.58 Amended and Restated Research and Development Agreement Vida Holdings
- 10.59 EX-10.59 Lease
- 23 EX-23 Consent of Ernst & Young LLP
- 31.1 EX-31.1 Section 302 Cert of CEO
- 31.2 EX-31.2 Section 302 Cert of CFO
- 32 EX-32 Section 906 Cert of CEO and CFO
Related press release
OTLC similar filings
Filing view
External links
Exhibit 10.55
AMENDMENT No. 2 TO
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT
This Amendment to Employment Agreement (the “Amendment”) is entered into as of January 20, 2009 (the “Amendment Effective Date”) by and between OXiGENE, Inc., a Delaware corporation (“OXiGENE”) and David Chaplin, Ph.D., an individual (the “Executive”), and amends the Employment Agreement (the “Agreement”) entered into by and between OXiGENE and Executive as of April 1, 2001 and amended as of January 1, 2007 and December 30, 2008. Pursuant to Section 9 of the Agreement, the Agreement is hereby amended as follows:
1. Section 6.2 (b) of the Agreement is hereby replaced with the following paragraph:
Payments equal to Executive’s then-current Base Salary for a period of sixteen (16) months, payable on OXiGENE’s normal paydays; plus
2. Section 6.3 (a) of the Agreement is shall be amended to include the following paragraph:
(ii) All stock options, stock appreciation rights, restricted stock and other incentive compensation granted to the Executive by OXiGENE shall vest and be immediately exercisable. Executive may exercise all such vested options and rights, and shall receive payments and distributions accordingly.
Except as set forth above, the Agreement shall remain in full force and effect according to its original terms.
OXiGENE, Inc. | ||||||||
/s/ David J. Chaplin | By: Name: | /s/ John A. Kollins | ||||||
Title: | Chief Executive Officer |